44 results on '"Paul, Sofia"'
Search Results
2. Intelligent Framework for Prediction of Heart Disease using Deep Learning
3. Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression
4. PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY
5. Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RARα Agonist, is a Novel Approach in AML
6. AML-347 SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy
7. SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy
8. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial
9. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.
10. Trial in progress: Phase I study of SY-5609, a potent, selective CDK7 inhibitor, with initial expansion in adults with metastatic pancreatic cancer.
11. Targeting RARAoverexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
12. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors
13. Intelligent Framework for Prediction of Heart Disease using Deep Learning
14. MM-392: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics
15. Poster: MM-392: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics
16. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
17. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
18. Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis
19. Clinical Endpoint
20. Clinical Endpoint
21. Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
22. DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).
23. DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.
24. Clinical Endpoint
25. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
26. Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
27. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
28. The Effects of Hormone Replacement Therapy and Raloxifene on C-Reactive Protein and Homocysteine in Healthy Postmenopausal Women: A Randomized, Controlled Trial*
29. Design and methods of the Raloxifene Use for The Heart (RUTH) study
30. PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE‐BASED THERAPY.
31. Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study
32. Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).
33. Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.
34. Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study
35. QT Interval Measurements in Patients with Hematologic Malignancies and Solid Tumors Treated with Oral Panobinostat (LBH589).
36. Population Pharmacokinetics of Panobinostat (LBH589) in Patients with Advanced Solid Tumors and Hematologic Malignancies Following Intravenous and Oral Administration.
37. Characteristics of Thrombocytopenia in Patients Treated with Oral Panobinostat (LBH589).
38. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates-A simulation study
39. PL-5 A phase III study of pemetrexed vs. docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) who were previously treated with chemotherapy
40. O-5 Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC)
41. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women
42. Modified ridge analyses under nonstandard
43. Raloxifene effects on vasomotor and other climacteric symptoms in postmenopausal women
44. Reproductive Endocrine and Endometrial Effects of Raloxifene Hydrochloride, a Selective Estrogen Receptor Modulator, in Women With Regular Menstrual Cycles
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.